ThromboGenics N.V. - Business Update (ncer cells. It is unique because in cont...)

ThromboGenics N.V. - Business Update

Date:5/13/2008

ncer cells. It is unique because, in contrast to competing agents, TB-403 only blocks blood vessels in tumour tissue and not in healthy tissue. This novel product, which acts on PIGF, is being co-developed with BioInvent International.

TB-403 is attracting growing interest from potential pharma partners based on both the need for improved products for the treatment of cancer and the exciting pre-clinical results which were published in a Cell feature article in the November 2, 2007 issue.(1)

The commercial potential of TB-403 could also be enhanced as TB-403 could also be used to treat a number of important back of the eye diseases. This is because common eye diseases such as age-related macular degeneration and diabetic retinopathy are caused by uncontrolled blood vessel growth, which could be halted using TB-403.

The Remainder of 2008

ThromboGenics expects to deliver a number of value creating clinical milestones during the remainder of 2008. The expected milestones over this period are:

Microplasmin

- Top line results are expected from the MIVI III Phase IIb trial of microplasmin in vitrectomy in June 2008.

ThromboGenics began the MIVI III Phase IIb trial in January 2007. The trial is evaluating the safety and efficacy of microplasmin intravitreal injection seven days prior to vitrectomy. The results from this trial will be presented at the World Ophthalmology Congress in Hong Kong on June 28, 2008.

Based on the results of this trial, ThromboGenics will select the best dose of microplasmin for use in two separate Phase III studies, one US and one European based. These trials, which are designed to clearly demonstrate the efficacy of microplasmin, are expected to begin before the end of 2008.

- Six month results from the MIVI IIT Phase IIa trial of microplasmin in vitreomacular traction are to be presented at the Euretina Conference in May.

The six month results from the first two cohorts of thi
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses

Post Your Comments:

ThromboGenics N.V. - Business Update(ncer cells. It is unique because in cont...)